The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,779.50
Bid: 1,779.00
Ask: 1,779.50
Change: 6.00 (0.34%)
Spread: 0.50 (0.028%)
Open: 1,780.00
High: 1,781.00
Low: 1,771.50
Prev. Close: 1,773.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-SSE says no break-up decision after report of Elliott pressure

Mon, 20th Sep 2021 08:33

* SSE backs current strategy

* Shares unchanged in early trading

* The Telegraph reported company was close to splitting
(Adds background, details, shares)

Sept 20 (Reuters) - Britain's SSE has not made a
decision to break itself up, the renewable power and networks
group said on Monday, after a newspaper report said it was close
to splitting up following months of pressure from U.S. activist
investor Elliott.

The company said it would update investors on growth plans
in due course. It is scheduled to report interim results in
mid-November.

FTSE 100-listed SSE, which has been sharpening its focus on
renewable power generation and electricity networks after the
sale of its retail division to OVO Energy, plans to invest 7.5
billion pounds ($10.3 billion) in low-carbon projects up to
2025.

The Telegraph newspaper reported on Friday https://bit.ly/3lE1yQe
that SSE was close to splitting into two separate blue-chip
companies.

"The Board remains fully focused on strategic choices which
will drive shareholder value from the wealth of net zero
opportunities the company is creating," the company said.

"SSE is currently building more offshore wind than any
company in the world, expanding internationally, and investing
in the low-carbon electricity infrastructure."

SSE shares have gained 9% this year, outperforming the
FTSE-100's 7% rise over the same period. In early Monday
trading, SSE stock was little changed.

Elliott, which recently targeted London-listed
pharmaceutical giant GSK, has been in talks with SSE's
board to separate the company's wholesale networks business from
its renewables operations for more than a year, the Telegraph
report added, citing unidentified sources.

Elliott's communications team did not immediately respond to
a Reuters request for comment.

Energy companies in Britain and across the world are under
the spotlight amid a surge in gas prices.

($1 = 0.7313 pounds)
(Reporting by Chris Peters and Muvija M in Bengaluru
Editing by Saumyadeb Chakrabarty and Mark Potter)

More News
18 Dec 2023 07:55

LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000

(Alliance News) - Stocks in London were set to retreat slightly on Monday, in line with equity markets in Asia, at the start of the last week before the Christmas holidays.

Read more
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.